Liver cancer is one of the most common malignancies in adults worldwide, particularly in Eastern Asia and Africa. Globally, over one million deaths per year can be attributed to liver cancer, which represent approximately 10% of all deaths worldwide.
A variety of signaling pathways, such as inflammatory, oxidative stress, autophagy, and apoptotic pathways, are implicated in the pathogenesis of liver cancer, and the interference of tumor suppressor and oncogene expression plays a vital role in the mechanisms giving rise to the initiation and development of liver cancer. Cancer cell signaling is an essential means of communication from the outside of the cell to the intracellular media, in addition to controlling a plethora of vital intracellular processes.
Although cancer research has progressed significantly in recent decades, it is imperative to understand the aberrant regulation of signaling pathways that give rise to tumor development in the liver, and study the relevant molecular targets warranting further investigation for antitumor therapies.
In this Research Topic, we aim to elucidate molecular and cellular signaling dysregulation in liver cancers, and focus on how a deeper understanding of aberrant signaling pathways can be utilised for therapeutic exploration. We welcome high-quality Original Research, Review, Mini-Review and Perspective articles in the subtopics, including but not limited to:
• Examination of the molecular mechanisms and dynamic interactions between immune cells and cancer cells in the liver, an immunologically privileged organ
• Exploration of novel upstream, downstream or crosstalk between key signaling pathways involved in HCC tumorigenesis - for example, the Hippo or Wnt/ß-catenin pathway
• Identification of novel potential biomarkers associated with the aberrant signaling pathways
• Novel targeted treatment modalities based on aberrant signaling pathways
• Association between aberrant biological behaviors and aberrant signaling pathways in liver cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Liver cancer is one of the most common malignancies in adults worldwide, particularly in Eastern Asia and Africa. Globally, over one million deaths per year can be attributed to liver cancer, which represent approximately 10% of all deaths worldwide.
A variety of signaling pathways, such as inflammatory, oxidative stress, autophagy, and apoptotic pathways, are implicated in the pathogenesis of liver cancer, and the interference of tumor suppressor and oncogene expression plays a vital role in the mechanisms giving rise to the initiation and development of liver cancer. Cancer cell signaling is an essential means of communication from the outside of the cell to the intracellular media, in addition to controlling a plethora of vital intracellular processes.
Although cancer research has progressed significantly in recent decades, it is imperative to understand the aberrant regulation of signaling pathways that give rise to tumor development in the liver, and study the relevant molecular targets warranting further investigation for antitumor therapies.
In this Research Topic, we aim to elucidate molecular and cellular signaling dysregulation in liver cancers, and focus on how a deeper understanding of aberrant signaling pathways can be utilised for therapeutic exploration. We welcome high-quality Original Research, Review, Mini-Review and Perspective articles in the subtopics, including but not limited to:
• Examination of the molecular mechanisms and dynamic interactions between immune cells and cancer cells in the liver, an immunologically privileged organ
• Exploration of novel upstream, downstream or crosstalk between key signaling pathways involved in HCC tumorigenesis - for example, the Hippo or Wnt/ß-catenin pathway
• Identification of novel potential biomarkers associated with the aberrant signaling pathways
• Novel targeted treatment modalities based on aberrant signaling pathways
• Association between aberrant biological behaviors and aberrant signaling pathways in liver cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
